ITM-22 is under clinical development by ITM Isotope Technologies Munich and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ITM-22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ITM-22 overview

ITM-22 is under development for the treatment of prostate cancer. The therapeutic candidate comprises of tumor-targeting molecule (TTM) conjugated to radioligand actinium-225. It acts by targeting cells expressing prostate-specific membrane antigen (PSMA).

ITM Isotope Technologies Munich overview

ITM Isotope Technologies Munich (ITM) is a biotechnology company that develops and produces therapeutic and diagnostic radiopharmaceuticals and radioisotopes to treat cancer. Its product portfolio includes radiolabeling and quality control equipment includes iQS theranostics synthesizer, iQS Ga-68 fluidic labeling module and reagent set for manual labeling of NCA 177Lu and biomolecules. It also provides radiopharmaceuticals and medical radioisotopes includes endolucinbeta and TOCscan. ITM’s pipeline products include ITM-11 for neuroendocrine tumors (GEP-NETs); ITM-31 for glioblastoma; ITM-24D / ITM-22 for prostate cancer; ITM-55D and ITM-52 for ovarian cancer and NSCL adenocarcinoma; ITM-41 for osteosarcoma and bone metastases. It has laboratories manufacturing radiopharmaceuticals. ITM is headquartered in Munich, Bavaria, Germany.

For a complete picture of ITM-22’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.